PDF(Pubmed)
Abstract：
Influenza vaccination is an important public health measure that can reduce disease burden, especially among older persons (those aged 65 and over) who have weaker immune systems. Evidence suggests enhanced vaccines, including adjuvanted quadrivalent vaccines (aQIV), may be particularly effective in this group. This study reports the results of a systematic review of the cost-effectiveness of aQIV in this population. The review was undertaken and reported in accordance with good practice guidelines. Medline and EMBASE were searched from 2013 to the present. Pre-selected eligibility criteria were employed and quality assessment undertaken using the Consensus Health Economic Criteria (CHEC-extended) checklist and Consolidated Health Economic Evaluation Reporting Standard (CHEERS) 2022 checklists. A total of 124 records were returned, with 10 full text papers retained. All were modelling studies and exhibited heterogeneity in approach, perspective, and parameter estimation. Nine papers reported cost-effectiveness ranging from EUR 6694/QALY to EUR 20,000/QALY in evaluations employing a payer perspective and from EUR 3936/QALY to EUR 17,200/QALY in those using a societal perspective. Results remained robust to a range of sensitivity analyses. One paper that reported contrary findings adopted a distinct modelling approach. It is reasonable to conclude that there is a broad consensus as to the cost-effectiveness of aQIV in this population group.
摘要：
接种流感疫苗是减轻疾病负担的重要公共卫生措施,尤其是免疫系统较弱的老年人（65岁及以上）。证据表明增强疫苗，包括佐剂四价疫苗(aQIV)，在该组中可能特别有效。本研究报告了对该人群中aQIV的成本效益进行系统评价的结果。审查是根据良好做法准则进行和报告的。从2013年至今搜索了Medline和EMBASE。采用预先选择的资格标准，并使用共识健康经济标准（CHEC扩展）清单和2022年综合健康经济评估报告标准（CHEERS）清单进行质量评估。总共返回了124条记录，保留了10篇全文论文。所有这些都是建模研究，在方法上表现出异质性，透视,和参数估计。九篇论文报告了采用付款人观点的评估中的成本效益从6694欧元/QALY到20,000欧元/QALY，而采用社会观点的评估中的成本效益从3936欧元/QALY到17,200欧元/QALY。结果对一系列敏感性分析仍然稳健。一篇报告相反结果的论文采用了一种独特的建模方法。可以合理地得出结论，关于aQIV在该人群中的成本效益存在广泛共识。
